Current recommendations for the systemic treatment of metastatic renal cell carcinoma

被引：2

作者：

Kroeger, Nils ^{[1
,2
]}

Merseburger, Axel S. ^{[3
]}

Bedke, Jens ^{[4
]}

机构：

[1] Urol Altstadtquartier, Erzberger Str 13, D-39104 Magdeburg, Germany

[2] Univ Med Greifswald, Klin & Poliklin Urol, Greifswald, Germany

[3] Univ Klinikum Schleswig Holstein, Urol, Campus Lubeck, Lubeck, Germany

[4] Eberhard Karls Univ Tubingen, Urol, Tubingen, Germany

来源：

AKTUELLE UROLOGIE | 2019年 / 50卷 / 06期

关键词：

renal cell carcinoma; prognosis; systemic therapy; guidelines; RANDOMIZED PHASE-3; INTERFERON-ALPHA; OPEN-LABEL; EVEROLIMUS; SUNITINIB; SORAFENIB; SURVIVAL; THERAPY; CABOZANTINIB; NIVOLUMAB;

D O I：

10.1055/a-0972-0788

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Numerous substances are available for the treatment of metastatic renal cell carcinoma (mRCC). Therefore, medical treatment of patients with mRCC has become a very complex subject. This review summarises clinical studies and typical side-effects of currently available agents that have been approved in Germany. The authors give suggestions for the use of these substances in the different therapy lines.

引用

页码：606 / 611

页数：6

共 19 条

[1]

[Anonymous], 2019, J CLIN ONCOL S

[2] Immune checkpoint inhibition in metastatic urothelial carcinoma [J].

Bedke, Jens ;

Todenhoefer, Tilman ;

Stenzl, Arnulf .

AKTUELLE UROLOGIE, 2018, 49 (02) :178-186

[3] Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma [J].

Choueiri, T. K. ;

Escudier, B. ;

Powles, T. ;

Mainwaring, P. N. ;

Rini, B. I. ;

Donskov, F. ;

Hammers, H. ;

Hutson, T. E. ;

Lee, J-L ;

Peltola, K. ;

Roth, B. J. ;

Bjarnason, G. A. ;

Geczi, L. ;

Keam, B. ;

Maroto, P. ;

Heng, D. Y. C. ;

Schmidinger, M. ;

Kantoff, P. W. ;

Borgman-Hagey, A. ;

Hessel, C. ;

Scheffold, C. ;

Schwab, G. M. ;

Tannir, N. M. ;

Motzer, R. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (19) :1814-1823

[4] Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update [J].

Choueiri, Toni K. ;

Hessel, Colin ;

Halabi, Susan ;

Sanford, Ben ;

Michaelson, M. Dror ;

Hahn, Olwen ;

Walsh, Meghara ;

Olencki, Thomas ;

Picus, Joel ;

Small, Eric J. ;

Dakhil, Shaker ;

Feldman, Darren R. ;

Mangeshkar, Milan ;

Scheffold, Christian ;

George, Daniel ;

Morris, Michael J. .

EUROPEAN JOURNAL OF CANCER, 2018, 94 :115-125

[5] RETRACTED: Immunotherapy for advanced renal cell cancer - art. no. CD001425.pub2 (Retracted Article) [J].

Coppin, C ;

Porzsolt, F ;

Awa, A ;

Kumpf, J ;

Coldman, A ;

Wilt, T .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (01)

[6] SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer [J].

Eichelberg, Christian ;

Vervenne, Walter L. ;

De Santis, Maria ;

von Weikersthal, Ludwig Fischer ;

Goebell, Peter J. ;

Lerchenmueller, Christian ;

Zimmermann, Uwe ;

Bos, Monique M. E. M. ;

Freier, Werner ;

Schirrmacher-Memmel, Silke ;

Staehler, Michael ;

Pahernik, Sascha ;

Los, Maartje ;

Schenck, Marcus ;

Floercken, Anne ;

van Arkel, Cornelis ;

Hauswald, Kirsten ;

Indorf, Martin ;

Gottstein, Dana ;

Michel, Maurice S. .

EUROPEAN UROLOGY, 2015, 68 (05) :837-847

[7] CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma [J].

Escudier, Bernard ;

Sharma, Padmanee ;

McDermott, David F. ;

George, Saby ;

Hammers, Hans J. ;

Srinivas, Sandhya ;

Tykodi, Scott S. ;

Sosman, Jeffrey A. ;

Procopio, Giuseppe ;

Plimack, Elizabeth R. ;

Castellano, Daniel ;

Gurney, Howard ;

Donskov, Frede ;

Peltola, Katriina ;

Wagstaff, John ;

Gauler, Thomas C. ;

Ueda, Takeshi ;

Zhao, Huanyu ;

Waxman, Ian M. ;

Motzer, Robert J. .

EUROPEAN UROLOGY, 2017, 72 (06) :962-971

[8] Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival [J].

Escudier, Bernard ;

Bellmunt, Joaquim ;

Negrier, Sylvie ;

Bajetta, Emilio ;

Melichar, Bohuslav ;

Bracarda, Sergio ;

Ravaud, Alain ;

Golding, Sophie ;

Jethwa, Sangeeta ;

Sneller, Vesna .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) :2144-2150

[9] Molecular Concepts of Immunomodulation for the Treatment of Metastatic Renal Cell Carcinomas: Where are We Now? [J].

Goebell, P. J. ;

Bedke, J. .

AKTUELLE UROLOGIE, 2015, 46 (06) :473-480

[10] Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma [J].

Hudes, Gary ;

Carducci, Michael ;

Tomczak, Piotr ;

Dutcher, Janice ;

Figlin, Robert ;

Kapoor, Anil ;

Staroslawska, Elzbieta ;

Sosman, Jeffrey ;

McDermott, David ;

Bodrogi, Istvan ;

Kovacevic, Zoran ;

Lesovoy, Vladimir ;

Schmidt-Wolf, Ingo G. H. ;

Barbarash, Olga ;

Gokmen, Erhan ;

O'Toole, Timothy ;

Lustgarten, Stephanie ;

Moore, Laurence ;

Motzer, Robert J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (22) :2271-2281

← 1 2 →